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Variant pharmacological activities of Zanthoxylum bungeanumwere determined before. The aim of this
study was to assess whether Z. bungeanum could regulate lipid metabolism. The cholesterol over-
loading HepG2 cells induced by sterols were used as in vitro model to study lipid-lowering activities of
the n-butanol (BuOH) fraction isolated from Z. bungeanum (ZBBu). Male apolipoprotein E knockout
(apoE-KO) mice with high fat diet were used as in vivo model. We ﬁrstly demonstrated ZBBu had
effects on reversed lipid accumulation, decreased apoB and enhanced apoA1 secretion. It increased the
amount of low density lipoprotein receptor (LDLR) protein, also signiﬁcantly inhibited the expression
of SREBP-1 and SREBP-2's target molecule (hydroxy methylglutaryl coenzyme A reductase, HMGCR),
which might be active in stimulation of RCT. And the expression of genes involved in RCT, such as
CYP27A1, LXR-a, ABCG1, was promoted by ZBBu. Furthermore, ZBBu could reduce serum TC, TG levels
in apoE-KO mice. Our study indicated that ZBBu could regulate the lipid metabolism through
increasing the amount of low density lipoprotein receptor (LDLR) and inducing the expression of genes
involved in RCT.
© 2014 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Atherosclerosis, the leading cause of death in modern society, is
a disease of lipid metabolism disorder as well as chronic inﬂam-
mation. The lipid homeostasis results from the balance between
synthesis and elimination. During the process of lipid biosynthesis
SREBP-1 plays an essential role in fatty acid and TG synthesis, while
SREBP-2 regulates the genes involved in cholesterol biosynthesis
(1), such as LDLR and HMGCR, a main rate-limiting enzyme of the
mevalonate pathway that produces cholesterol and other iso-
prenoids. Low density lipoprotein cholesterol (LDL-c) has been
considered to be “bad cholesterol” which results in an increased
risk of atherosclerosis. When in excess it can deposit in artery and
initiates atherosclerosis. And its clearance can be mediated by
hepatic LDLR (2). Differ from LDL-c, high density lipoprotein: þ86 21 51980018.
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not only to reverse cholesterol transport, but also to provide anti-
oxidant enzymes (3). During the process of lipid elimination, ATP-
binding cassette (ABC) transporters play important roles in
exporting free cholesterol (FC) to extracellular apolipoproteins,
such as apoB and apoA1 (4), which is called RCT. The interplay of
those factors makes cholesterol stay balanced.
Zanthoxylum bungeanum belongs to the rutaceae family and has
been widely used as aromas in China and reported to possess a
broad diversity of structures and functions. In modern research,
cardiac protective activity of Z. bungeanum fruit has been reported
for its essential oil (5). Ethanol extract (6) is considered to be useful
in circulation. The antioxidant activity of methanol extract from Z.
bungeanum is also found by Yamazaki et al. (7). But there still are
not any reports about the effects of Z. bungeanum on lipid meta-
bolism, which is what we investigated in our study.
Since the regulation of hepatic LDLR and HMGCR activity can be
observed in HepG2 cells, previous literatures always use HepG2
cells to study lipid metabolism (8). The role of exogenous lipid as
modulator of hepatic cholesterol synthesis and apoB containing
lipoprotein secretion has been well established. Intracellular lipid
or cholesterol ester accumulation and apoB secretion are not onlyr B.V. All rights reserved.
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by addition of 25-hydroxycholesterol (9). Incubated with 50 mg/ml
cholesterol and 4 mg/ml 25-hydroxycholesterol for 24 h, HepG2
accumulates approximately 2.0-fold greater apoE and apoB as
compared to BSA-treated cells, while reduces mRNA and activity of
LDL receptor (10). So combination of cholesterol and 25-
hydroxycholesterol were applied to establish HepG2 cells choles-
terol over-loading model. And the study of Yucun Niu gave us an
evident that this model might be used to screen and assess func-
tional factors for lowering lipids (11). In our present study,
cholesterol and 25-hydroxycholesterol in cultured cells were
shown to signiﬁcantly elevate lipid accumulation, increase apoB
secretion, as well as repress genes encoding proteins involved in
cholesterol biosynthesis by feedback (12). Hence we undertook the
present model to investigate how ZBBu affects lipid metabolism in
normal condition and reverse lipid accumulation caused by exog-
enous sterols.
In our previous study, we compare the effects of three fractions
isolated from Z. bungeanum (petroleum ether fraction, ethyl acetate
fraction and n-butanol fraction) on regulating the cholesterol
metabolism in HepG2 cells and ﬁnd ZBBu is best effective; we also
has demonstrated its pharmacological activity in reducing oxida-
tive stress and inﬂammation in vivo (13). Assays including thin-
layer chromatography (TLC) and high-performance liquid chro-
matography/mass spectrometry (HPLCeMS) have been used to
investigate its chemical compositions, which revealed the presence
of many ﬂavone glycosides. Dietary ﬂavonoids show the protective
activity in inhibiting the thrombus formation, overcoming
damaging effects of cardiovascular risk factors and delaying the
onset of atherosclerosis (14,15). In the context of these evidences




HepG2 cells were obtained from American Type Culture
Collection (ATCC). Z. bungeanum fruit (Family: Rutaceae) was pur-
chased from Sichuan province, China. The standard substances
(Rutin, Hyperin) were purchased from Shanghai R&D Center for
Standardization of Traditional Chinese Medicines (Shanghai,
China). 25-hydroxycholesterol and cholesterol were obtained from
Sigma (MO, USA). Dulbecco's Modiﬁed Eagle's medium (DMEM)
and fetal bovine serum (FBS) were purchased from Invitrogen (CA,
USA). Total RNA extraction reagent, reverse transcription kit, and
SYBR Premix Ex Taq (Tli RNaseH plus) were purchased from
TAKARA (Japan). Antibodies against SREBP-1, HMGCR and LDLR
were acquired from Santa Cruz (TX, USA), Abcam (MA, USA) and
R&D (MN, USA) respectively. Intracellular TC, FC, FFA and TG
quantiﬁcation kits were obtained from Applygen Technologies Inc.
(Beijing, China). Biochemical reagents assessing TC, TG levels in the
serum samples were purchased from NanJing JianCheng Bioengi-
neering Institute (Nanjing, China). Human apoB and apoA1 ELISA
kit were purchased from Assaypro (MO, USA) and Shanghai Hufeng
Biotechnology Company (Shanghai, China) respectively. BCA pro-
tein assay kit was purchased from Shanghai Biocolor BioScience &
Technology Company (Shanghai, China).
2.2. Extraction
Z. bungeanum fruit was extracted with 95% ethanol by 50 C
heating reﬂux method for 3 times (16). The extractions were dried
in a vacuum rotary evaporator to a yield of 33.3%, which was then
suspended in H2O and partitioned with petroleum ether (PE), ethylacetate (EtOAc) and n-butanol (BuOH) successively (17). These
three fractions were dried by vacuum at 40 C and the yield of PE,
EtOAc and BuOH were 2.7%, 16.7%, and 12%. We have valued the
activities of these three fractions, and found the fraction of BuOH
was the most prospective, which was used for further experiment.
2.3. Chromatographic ﬁngerprint
In our previous study, we found rutin and hyperin presented in
ZBBu. And preliminary HPLC study of ZBBu and comparison with
standards (rutin, hyperin) also indicated the presence of these
compounds in the extract. The dried extract of ZBBu was dissolved
in methanol at the concentration of 0.5 mg/ml and ﬁltered through
a 0.2-mm Millipore ﬁlter. 2 ml of methanol solution was used for
HPLC analysis (Agilent 1260). We applied agilent eclipse plus C18
(3.5 mm  2.1 mm  100 mm) to separate the ZBBu fraction with a
column temperature of 29 C. The mobile phase comprised a binary
eluent of 0.05% aqueous formic acid (A) and acetonitrile (B) using a
liner gradient program of 5%e18% B, 0e3 min; 18% B, 3e10 min;
18%e63% B, 10e20 min; 63% B, 20e25 min. It was delivered at a
ﬂow rate of 0.3 ml per min with detection at 254 nm.
2.4. Cell culture
All of the testing solutions were dissolved with ethanol as stock
solution, which were diluted to the needed concentration with
DMEM. The HepG2 was maintained in DMEM supplemented with
10% FBS in the presence of 100 U/ml penicillin and 100 U/ml strep-
tomycin, and incubated at 37 C under the atmosphere of 5% CO2.
24 h after seeding, DMEM was removed. HepG2 cells were washed
twice with PBS and incubated in serum-free DMEM supplemented
with different concentrations of ZBBu, 100 mM hyperin and 40 mM
rutin for 12 h. Then 1104 mmol/L Cholesterolþ 1 103 mmol/L 25-
hydroxycholesterolwere dissolved in ethanol, dilutedwithDMEMto
10 mmol/L Cholesterolþ 1 mmol/L 25-hydroxycholesterol and added
to cells. The samevolumeof ethanolwas added to thecontrol cells. To
validate this model, simvastatin (1 mM), a well-established drug to
treat atherosclerosis, was used as a positive control. After another
24 h, monolayers were washed three times with PBS and harvested.
Under present condition, the ﬁnal concentration of ethanol did not
exceeded 0.1%. Exogenous cholesterol and 25-hydroxycholesterol
did not affect the growth of HepG2 cells.
2.5. Animals
Male C57BL/6 mice and male apoE-knockout (apoE-ko) mice
(6e8 weeks) in the C57BL/6 background were purchased from
Beijing HFK Bio-Technology Co. Ltd. and maintained in SPF room
with 12 h light/dark cycle. C57BL/6 mice as normal control group
were fed a chow diet. apoE KO mice were given high fat diet and
randomly divided into 4 groups with 6 animals each: the model
group (high fat diet only), positive control group (simvastatin,
3mg/kg/d), low dose group (ZBBu 50mg/kg/d) and high dose group
(ZBBu 200 mg/kg/d), administered by oral gavage for 4 weeks. At
the end, blood was collected after overnight fasting and then
centrifuged to get serum (3000 rpm, 10 min, 4 C). All mice used
were handled according to the guidelines of the Instituted Animal
Care and Use Committee of Fudan University for the care and use of
laboratory animals.
2.6. Determination of intracellular TC, FC, FFA and TG
The harvested cells were incubated with lysis buffer and
centrifuged to get the supernatant. Then the contents of intracel-
lular TC, FC, FFA and TGwere determined using standard enzymatic
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centration was measured using BCA kit.
2.7. Secreted apoB and apoA1
Levels of apoB, apoA1 in supernatant of HepG2 were deter-
mined according to manufacturer's instruction with an automatic
biochemical analyzer (Au5600 OLYMPUS). After the incubation,
the culture medium was collected and added into 96-well plate
coated with an anti-human ApoB/ApoA1 polyclonal antibody
(purchased from Assaypro) and incubated for 2 h at room tem-
perature. The 96-well plate was washed ﬁve times with wash
buffer. Then biotinylated human ApoB antibody was added and
incubated for 1 h. The 96-well plate was washed ﬁve times before
incubated with streptavidineperoxidase conjugate for another
30 min, then chromogenic substrate and stop solution were
added successively. Absorbance was read at a wavelength of
450 nm.
2.8. RNA isolation and real-time RT-PCR
Total RNA was isolated from HepG2 cells with TRI-zol reagent
and reverse-transcribed using Real-time PCRmaster mix. Real-time
PCR reaction was performed using Bio-Rad™ iQ5 real-time PCR
optical detection system. Final results were standardized to the
expression of b-actin, and values were expressed relatively to the
average values for negative control, which was set to 1.0. Real-time
PCR primer sequences were as below:
b-actin: forward, 50-AGCCATGTACGTAGCCATCC-30, reverse, 50-
CTCTCAGCTGTGGTGGTGAA-30; SREBP-2: forward, 50-GCAACAACA
GACGGTAATGATC-30, reverse, 50-GACTTGAGGCTGAAGGACTTG-30;
HMGCR: forward, 50-ACATTGTCACCGCCATCTACATTGC-30; reverse,
50-GGCTTGCTGAGGTAGTAGGTTGGT-30; LDLR: forward, 50-CTGTCT
CTGTTGCGGATACCAAGG-30, reverse, 50-GCGAGTAGATGTCCACAC
CATTCA-30; LXR-a: forward, 50-ATGGACACCTACATGCGTC-30,
reverse, 50-CTTCAGGCGGATCTGTTCTT-30; ABCG1: forward, 50-TGCFig. 1. Chromatogram of standard substances and ZBBu. A: the chromatogram oAATCTTGTGCCATATTTGA-30, reverse, 50-CCAGCCGACTGTTCT
GATCA-30; CYP27A1: forward, 50-AGATGCAGCTACTCCTCGCAA-30,
reverse, 50-AGGCCCACTTTCTTATTGGGA-30.
2.9. Western blotting analysis
After incubation, cells were washed with PBS and then treated
with lysis buffer containing PMSF. After protein quantitation,
protein samples were equally loaded onto 8% poly-acrylamide
gel, electrophoresed, and transferred onto a PVDF membrane.
Membranes were blocked with 5% defatted milk in TBS con-
taining 0.1% Tween 20 at room temperature for 1 h, incubated
overnight at 4 C with HMGCR, LDLR and SREBP-1 primary
antibody, and then with horseradish peroxidase conjugated
secondary antibody. The immunoreactivity was visualized using
the ECL chemiluminescence kit according to the manufacturer's
instructions, recorded by Alpha gel imaging system and quanti-
tated by Image J.
2.10. Determination of TC, TG levels in serum
Serum TC, TG levels were assessed using the biochemical re-
agent kits according to manufacturer's instructions.
2.11. Statistical analysis
Data was expressed as means ± SD. Signiﬁcance differences
were assessed by one-way ANOVA and student t-test. P < 0.05 was
considered to be statistically signiﬁcant.
3. Results
3.1. HPLC analysis
The Analysis of ZBBu by HPLC revealed rutin and hyperin
were existed in ZBBu, which was identiﬁed by their retentionf standard substances. B: the chromatogram of ZBBu. 1, Rutin; 2, Hyperin.
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and hyperin presenting in ZBBu were approximately 12.12% and
31%.
3.2. ZBBu affects intracellular TC, FC, FFA and TG
To study ZBBu further, HepG2 cells were initially maintained in
serum-free DMEM to create a reduced-sterol environment, and
then pretreated with 0.05 mg/ml, 0.1 mg/ml, 0.2 mg/ml ZBBu or
vehicle. In previous study, it was demonstrated that addition of 25-
hydroxycholesterol was highly effective in altering theFig. 2. Effects of ZBBu on intracellular TC, FFA, FC and TG. HepG2 cells, were pretreated wit
were exposed to 10 mg/ml cholesterol and 1 mg/ml 25-hydroxycholesterol or only vehicle f
intracellular level of TC, FFA, TG, FC. 0.2 mg/ml ZBBu had similar effect to Rutin and hyperin
treatment of sterols and presented as means ± SD. The mean of at least 3 independent expe
control group treated with 25OH þ cho. #P < 0.05, ##P < 0.01 compared these two controlconcentration of cellular lipids (9). As expected, with this treatment
the intracellular TC level was increased signiﬁcantly (Fig. 2A), as
well as TG (Fig. 2C) and FC (Fig. 2D), but we found no increase in FFA
(Fig. 2B). After exposure to ZBBu, TG could be dose-dependently
decreased both in the absence and presence of sterols (P < 0.01).
Similarly, TC, FC and FFA were also reduced. Higher dosage of ZBBu
in current experiment status showed similar lipid-lowing effect to
simvastatin.We also valued the effect of hyperin and rutin. Our data
indicated that 100 mM hyperin and 40 mM rutin could decrease
intracellular TC (Fig. 2E) and FC (Fig. 2F), which might account for
the effect of ZZBu.h different concentrations of ZBBu or 100 mM hyperin, 40 mM rutin for 12 h. Then cells
or 24 h. TC (A, E), FFA (B), TG (C) or FC (D, F) was evaluated. ZBBu could decrease the
(E, F). Data are normalized to total protein, expressed as a ratio to the control without
riments is shown. $P < 0.05, $$P < 0.01 versus normal group. *P < 0.05, **P < 0.01 versus
groups. Ctrl: control. Sim: simvastatin. 25OH: 25-hydroxycholesterol. Cho: cholesterol.
Fig. 3. Effects of ZBBu on apoB and apoA1 secretion. HepG2 cells were pretreated with 0.05 mg/mle0.2 mg/ml ZBBu for 12 h and stimulated with sterols for 24 h. After the
treatment, apoB and apoA1 in supernatants were evaluated by ELISA. ZBBu could reverse the increased level of apoB induced by 25OH þ cho (A). And ZBBu promoted the secretion
of ApoA1 (B). Data are expressed as ratios to the control without treatment of sterols and presented as means ± SD. The mean of at least 3 independent experiments is shown.
$P < 0.05, $$P < 0.01 versus normal group. *P < 0.05, **P < 0.01 versus control group treated with 25OH þ cho. #P < 0.05 compared these two control groups. Ctrl: control. Sim:
simvastatin. 25OH: 25-hydroxycholesterol. Cho: cholesterol.
Fig. 4. Effects of ZBBu on mRNA and protein expression of HMGCR and LDLR. Western blotting of LDLR (mature form) and HMGCR protein (A) ZBBu treatment increased LDLR
protein expression (B) while inhibited LDLR mRNA (D) abundance. It also showed down-regulation of HMGCR both on protein level (C) and mRNA level (E) in HepG2 cells. Data are
expressed as ratios to the control without treatment of sterols, and presented as means ± SD. The mean of at least 3 independent experiments is shown. $P < 0.05, $$P < 0.01 versus
normal group. **P < 0.01 versus control group treated with 25OH þ cho. #P < 0.05, ##P < 0.01 compared these two control groups. Ctrl: control. Sim: simvastatin. 25OH: 25-
hydroxycholesterol. Cho: cholesterol.
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Apolipoprotein B (apoB) is a structural protein of LDL and very
low density lipoprotein (VLDL) (18). We ﬁrstly studied the ability of
ZBBu affecting apoB secretion in HepG2 cells in normal physio-
logical status. HepG2 cells pretreated with ZBBu had an inhibitory
effect on apoB secretion, although it wasn't shown to be dose-
dependent. The amount of apoB secreted by HepG2 cells was
elevated upon addition of exogenous sterols. Both treatment with
ZBBu and simvastatin attenuated the induction of apoB secretion
(Fig. 3A).
We also investigated whether ZBBu affected the production of
apoA1, the major structural protein of HDL. Overexpression of HDL
or apoA1 can reduce the risk of atherosclerosis (19). Fig. 3B has
shown to us that 0.2 mg/ml ZBBu and simvastatin led to an increase
of apoA1 in the absence of sterols. After exposure to cholesterol and
25-hydroxycholesterol, ZBBu also exerted a dose-dependent stim-
ulatory effect on apoA1 secretion (P < 0.05), which was more
effective than positive control drug.Fig. 5. ZBBu inhibited SREBP-1 and SREBP-2 expression. Western blotting of SREBP-1 protei
(C). D, abundance of SREBP-2 mRNA. Data are expressed as ratios to the control without tr
experiments is shown. $P < 0.05, $$P < 0.01 versus normal group. *P < 0.05, **P < 0.01 vers
control groups. Ctrl: control. Sim: simvastatin. 25OH: 25-hydroxycholesterol. Cho: choleste3.4. Effects of ZBBu on genes and proteins expression of cholesterol
biosynthesis enzymes
In consideration of the notable changes in intracellular lipids
and secretion of apoB and apoA1 accompanying ZBBu treatment,
we tried to ﬁnd out how it affected the lipid homeostasis. The re-
sults in Fig. 4C and E showed that ZBBu treatment decreased
HMGCR protein and mRNA at a dose-dependent manner in
depletion of sterols. When sterols were supplemented to the cells,
which were condition to inhibit endogenous cholesterol synthesis
by negative feedback, HMGCR protein and mRNA expressions were
suppressed. However, treated with ZBBu, HMGCR protein and
mRNA were further reduced.
Hepatocyte LDLR can regulate apoB secretion by controlling the
uptake of newly secreted particles and degradation of nascent
apoB (20). The potential of ZBBu inhibiting apoB secretion leaded
us to investigate the expression of LDLR mRNA and protein. A
lower LDLR gene expression in ZBBu treated groups was observed
as compared to the control group (Fig. 4D). Sterols decreased LDLRn (precursor and mature form) (A), and quantiﬁcation after normalizing by GADPH (B),
eatment of sterols, and presented as means ± SD. The mean of at least 3 independent
us control group treated with 25OH þ cho. #P < 0.05, ##P < 0.01 compared these two
rol.
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In agreement with the changes in LDLR mRNA abundance, sterols
also suppressed LDLR protein expression. However, ZBBu treat-
ment signiﬁcantly increased LDLR protein expression (P < 0.01),
although there was no great difference among the three groups
(Fig. 4B).
Because of the effects on HMGCR and LDLR, we predicted that
ZBBu might cause some changes in the expression of their regu-
latory factors such as SREBP-1 and SREBP-2. The result of present
study showed that the active SREBP-1 mature protein was dose-
dependently decreased with the pretreatment of ZBBu (Fig. 5B).
After exposure to sterols for 24 h, the expression of SREBP-1 was
restrained comparing with vehicle group. Similar to simvastatin,
treatment of ZBBu signiﬁcantly further lowered expression of
SREBP-1 (both precursor and mature form). SREBP-2, which regu-
lates HMCGR, is affected by intracellular and extracellular choles-
terol. Fig. 5D showed SREBP-2 mRNA abundance was down
regulated by ZBBu in both normal condition and the presence of
exogenous sterols.3.5. Effects of ZBBu on the expression of cholesterol efﬂux related
factors in HepG2 cells
To explore whether ZBBu inﬂuenced the gene involved in RCT,
we used real-time PCR to assess relative changes in the expression
of gene LXRa, ABCG1 and CYP27A1. The results showed that pre-
treatment of ZBBu dose-dependently enhanced the mRNA abun-
dance of CYP27A1, LXRa and ABCG1 both in the presence and
absence of sterols (Fig. 6).Fig. 6. Effects of ZBBu on genes' expression involved in RCT. ZBBu increased the mRNA expre
(B) and subsequently ABCG1 (C). Data are expressed as ratios to the control without trea
experiments is shown. $P < 0.05, $$P < 0.01 versus normal group. *P < 0.05, **P < 0.01 vers
hydroxycholesterol. Cho: cholesterol.3.6. Effects of ZBBu on serum lipid levels in apoE-ko mice
To conﬁrm the hypolipidemic effect of ZBBu in vivo, we used
apoE KO mice fed with high fat diet to induce animal hyperlipid-
emia model. After 4 weeks high fat diet, the serum TC and TG levels
in the model group were up-regulated, indicating that the animal
hyperlipidemia model was successfully established. ZBBu applica-
tion could signiﬁcantly inhibit the hyperlipidemia effects
(increased serum TC and TG level) caused by the high fat diet,
which was similar with the effect of Simvastatin, as shown in Fig. 7.
4. Discussion
In consideration of anti-inﬂammation or anti-septic activities of
Z. bungeanum have been studied before, here we extracted the
BuOH fraction from ethanol extract of Z. bungeanum and identiﬁed
that ZBBu effectively regulated lipid metabolism and worked
through a similar way to simvastatin.
In this study, we demonstrated the hypolipidemic effects of
ZBBu both in vitro and in vivo. Many ﬂavonoid glycosides, such as
rutin and hyperin were found in the component of ZBBu. As a
member of polyphenols, ﬂavonoid glycoside could regulate lipid
metabolism through meditating lipoprotein lipase expression (21),
suppress progression of atherosclerosis in vivo (22) and alter
cholesterol homeostasis by increasing the expression of LDLR (23).
In vitro, rutin lowers the HMGCR activity to reduce the cholesterol
metabolism (24,25). The effects of rutin and hyperin on lipid
metabolism are also proved in vivo (26e28). So the ﬂavonoid
glycoside existing in ZBBu would account for the regulation func-
tion of ZBBu on cholesterol homeostasis.ssion of CYP27A1 (A). Activation of CYP27A1 stimulated the mRNA abundance of LXR-a
tment of sterols, and presented as means ± SD. The mean of at least 3 independent
us control group treated with 25OH þ cho. Ctrl: control. Sim: simvastatin. 25OH: 25-
Fig. 7. Effects of ZBBu on serum lipid levels in vivo. High fat diet increased the serum lipid levels in model group signiﬁcantly. Treated with ZBBu, the increased levels of serum TC (A)
and TG (B) were attenuated in high fat group. Data are presented as means ± SD (n ¼ 6). **P < 0.01 versus model group. ##P < 0.01 versus control group. Ctrl: control. Sim:
simvastatin. HF: high fat diet.
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fatty acid synthesis. SREBP-2 is primarily responsible for regulating
the cholesterol biosynthesis genes (2,29). Using the cell model
above, the results showed that ZBBu down-regulated the expres-
sion of SREBP-1, SREBP-2 and HMGCR, which could explain the fact
of lower intracellular TC, TG, FG and FFA levels. LDLR is one of
another genes regulated by SREBPs. Interestingly, ZBBu stimulated
the protein abundance of LDLR in HepG2 cells, leading to the
observation of decreased apoB secretion. The down-regulation of
LDLR on cell surface enhanced levels of LDL-c in the plasma (30).
Elevated plasma LDL-c has a great association with the develop-
ment of coronary atherosclerosis (31). In the arterial intima, LDL-c
can be oxidatively modiﬁed by oxygen species forming Ox-LDL,
which can initiate the atherosclerotic process (32). So the effect
of ZBBu on LDLR could inhibit the process of atherosclerotic.
What's more, we recognized the ZBBu might affect other path-
ways involved in lipid metabolism. Liver X receptor-alpha (LXRa)
has been proposed to be an important regulator involved in HDL-c
metabolism and bile acid (33). Its agonists promote cholesterol
efﬂux, accelerated RCT or anti-atherosclerosis (34). And several
important genes for lipid metabolism, such as ABCA1 and ABCG1,
have been shown to be responsible to LXRa. Accordingly, the
therapies focused on RCT becomes a target to treat atherosclerosis.
LXRa can be stimulated by CYP27A1. The importance of CYP27A1
for bile acid synthesis has long been documented. Liver can elimi-
nate cholesterol by CYP27A1 mediating formation of cholestenoic
acid. Being exposed to ZBBu, CYP27A1, LXRa and ABCG1 mRNA
levels in HepG2 cells were increased. ABCG1 promotes the efﬂux of
cholesterol from cells to particles containing lipid-poor apoA1 (35).
Regulated by LXRa, ABCG1 was further affected by CYP27A1. Acti-
vation of these genes has favorable effects on chronic metabolism
of lipids (36). In the RCT, excess cellular cholesterol from peripheral
tissues could efﬂux to mature HDL particles mediated by ABCG1.
Furthermore, cholesterol, which was transported by the HDL par-
ticles, could return to the liver for excretion from bile and ulti-
mately feces (37). Modiﬁcation of RCT and cholesterol efﬂux may
provide new therapeutic approaches to cardiovascular disease,
which plays a major role in anti-atherogenesis (38). Considering
the inﬂuence of ZBBu on RCT, ZBBu may further suppress the pro-
cess of atherosclerosis.
As the effects of ZBBu in vitro had been proved, we wanted to
ﬁgure out whether it could work on lipid metabolism in vivo. ApoE,
as a ligand of LDLR, has an important role in lipid metabolism. And
apoE deﬁciency is associated with dyslipidemia (39). Then we
chose apoE KO mice which were fed with high fat diet as animal
model. It was awidely used hyperlipidemiamodel. As expected, the
results of animal experiment demonstrated that ZBBu could alsoinﬂuence the lipid metabolism in vivo, reducing serum TC and TG
dose-dependently. Further study will be carried out to determine
the pathologic change and molecular mechanism undergoing
in vivo.
In conclusion, decreased lipid biosynthesis in vivo and in vitro,
increased LDLR protein expression and genes involved in RCT
in vitro could account for the hypolipidemic effects of ﬂavonoids-
rich ZBBu. Therapies targeting the interplay between lipid meta-
bolism and inﬂammation have potential in the treatment of
atherosclerosis. In the context of the evidences, we predicted the
ZBBu might exert biological effects on the pathogenesis of
atherosclerosis.
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